Ahmedabad: Pharma major, Zydus Lifesciences Limited, has received tentative approval from the United States Food and Drug ...

As per the IQVIA data (March, 2025), the Rifaximin tablets had annual sales of $2,672.9 million in the US market.

Zydus Lifesciences receives USFDA approval for Rifaximin Tablets, a generic treatment for Irritable Bowel Syndrome with ...

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin Tablets, 550 mg (USRLD: Xifaxan Tablets, 550 mg).

The said facility underwent an inspection Between 10-14 March, 2025, and the inspection has been classified as No Action ...

Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin tablets, 550 mg, under the reference listed drug (RLD) ...

Zydus Lifesciences receives FDA tentative approval for Rifaximin Tablets, 550 mg, for IBS-D treatment in adults.

The deal values each share at $7.50, with the acquisition to be completed in cash within 60 days, subject to applicable ...

Zydus Lifesciences has received tentative approval from the US Food and Drug Administration to market Rifaximin Tablets in the United States. These tablets are designed to treat irritable bowel ...